Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CRBP Stock Price Chart
Explore Corbus Pharmaceuticals Holdings, Inc. interactive price chart. Choose custom timeframes to analyze CRBP price movements and trends.
CRBP Company Profile
Discover essential business fundamentals and corporate details for Corbus Pharmaceuticals Holdings, Inc. (CRBP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Oct 2014
Employees
28.00
Website
https://www.corbuspharma.comCEO
Yuval Cohen
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Financial Timeline
Browse a chronological timeline of Corbus Pharmaceuticals Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.73.
Earnings released on 5 Aug 2025
EPS came in at -$1.44 surpassing the estimated -$1.55 by +7.10%.
Earnings released on 6 May 2025
EPS came in at -$1.39 falling short of the estimated -$1.26 by -10.32%.
Earnings released on 11 Mar 2025
EPS came in at -$0.78 surpassing the estimated -$1.02 by +23.53%.
Earnings released on 7 Nov 2024
EPS came in at -$1.15 falling short of the estimated -$0.99 by -16.16%.
Earnings released on 6 Aug 2024
EPS came in at -$0.90 surpassing the estimated -$1.16 by +22.41%.
Earnings released on 7 May 2024
EPS came in at -$0.83 surpassing the estimated -$1.09 by +23.85%.
Earnings released on 12 Mar 2024
EPS came in at -$1.81 surpassing the estimated -$2.36 by +23.31%, while revenue for the quarter reached $1.35M .
Earnings released on 7 Nov 2023
EPS came in at -$2.27 falling short of the estimated -$2.06 by -10.19%.
Earnings released on 8 Aug 2023
EPS came in at -$2.05 surpassing the estimated -$3.10 by +33.87%.
Earnings released on 9 May 2023
EPS came in at -$4.24 falling short of the estimated -$4.09 by -3.67%.
Earnings released on 7 Mar 2023
EPS came in at -$2.61 falling short of the estimated -$2.10 by -24.29%.
Stock split effective on 14 Feb 2023
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2022
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%.
Earnings released on 9 Aug 2022
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%.
Earnings released on 10 May 2022
EPS came in at -$2.40 surpassing the estimated -$2.70 by +11.11%.
Earnings released on 8 Mar 2022
EPS came in at -$2.40 surpassing the estimated -$3.30 by +27.27%, while revenue for the quarter reached -$881.71K , missing expectations by -353.73%.
Earnings released on 12 Nov 2021
EPS came in at -$0.60 surpassing the estimated -$3.60 by +83.33%, while revenue for the quarter reached $97.32K , missing expectations by -84.05%.
Earnings released on 12 Aug 2021
EPS came in at -$4.50 falling short of the estimated -$3.60 by -25.00%, while revenue for the quarter reached $136.56K , missing expectations by -0.32%.
Earnings released on 13 May 2021
EPS came in at -$4.20 surpassing the estimated -$4.50 by +6.67%, while revenue for the quarter reached $647.82K , missing expectations by -6.25%.
Earnings released on 15 Mar 2021
EPS came in at -$3.00 surpassing the estimated -$6.61 by +54.61%, while revenue for the quarter reached $658.20K .
Earnings released on 10 Nov 2020
EPS came in at -$12.91 falling short of the estimated -$12.31 by -4.87%, while revenue for the quarter reached $1.23M .
CRBP Stock Performance
Access detailed CRBP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.